{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-118261","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.359283+00:00","generated_at":"2026-05-30T00:31:30.017888+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioXcel Therapeutics Q3 2024 net loss narrows to $13.7M; advances Phase 3 trials for agitation","bullets":["Net loss of $13.7M in Q3 2024 vs $50.5M loss in Q3 2023; operating cash use $16.3M.","IGALMI net revenue $214k in Q3, down from $341k YoY; nine-month revenue $1.9M, up 89%.","R&D expenses $5.1M vs $19.6M; SG&A $7.7M vs $24.3M, both lower due to restructuring.","First patient randomized in SERENITY At-Home Phase 3 trial for bipolar/schizophrenia agitation; 9-12 month duration.","Cash and equivalents $40.4M as of Sept 30, 2024; patent portfolio extended to 2043."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-118261","json":"https://secwatch.observer/filing/0001104659-24-118261.json","markdown":"https://secwatch.observer/filing/0001104659-24-118261.md","text":"https://secwatch.observer/filing/0001104659-24-118261.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924118261/0001104659-24-118261-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465924118261/tm2428378d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:31:30.017888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}